TY - JOUR
T1 - Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era
T2 - a retrospective study by the EBMT Lymphoma Working Party
AU - Hübel, Kai
AU - Re, Alessandro
AU - Boumendil, Ariane
AU - Finel, Herve
AU - Hentrich, Marcus
AU - Robinson, Stephen
AU - Wyen, Christoph
AU - Michieli, Mariagrazia
AU - Kanfer, Edward
AU - Diez-Martin, Jose Luis
AU - Balsalobre, Pascual
AU - Vincent, Laure
AU - Schroyens, Wilfried
AU - Santasusana, Josep Maria Ribera
AU - Kröger, Nicolaus
AU - Schiel, Xaver
AU - Cwynarski, Kate
AU - Esquirol, Albert
AU - Sousa, Aida Botelho
AU - Cattaneo, Chiara
AU - Montoto, Silvia
AU - Dreger, Peter
PY - 2019/10/1
Y1 - 2019/10/1
N2 - The present study aimed at describing the outcome of patients with HIV-associated lymphomas following autologous hematopoietic stem cell transplantation (autoHCT) in the rituximab and combined antiretroviral therapy (cART) era. Eligible for this retrospective study were HIV-positive patients with lymphoma who received autoHCT between 2007 and 2013. A total of 118 patients were included with a median age of 45 years (range 24–66). Underlying diagnoses were diffuse large B cell lymphoma in 47%, Hodgkin lymphoma in 24%, Burkitt lymphoma in 18%, and plasmablastic lymphoma in 7% of patients. Disease status at autoHCT was complete remission in 44%, partial remission (PR) in 38%, and less than PR in 18% of the patients. With a median follow-up of 4 years, 3-year non-relapse mortality, incidence of relapse, progression-free survival (PFS) and overall survival (OS) were 10%, 27%, 63% and 66%, respectively. By multivariate analysis, disease status less than PR but not CD4+ cell count at the time of autoHCT was a significant predictor of unfavorable PFS and OS. In conclusion, in the era of cART and chemoimmunotherapy, the outcome of autoHCT for HIV-related lymphoma is driven by lymphoma-dependent risk factors rather than by characteristics of the HIV infection.
AB - The present study aimed at describing the outcome of patients with HIV-associated lymphomas following autologous hematopoietic stem cell transplantation (autoHCT) in the rituximab and combined antiretroviral therapy (cART) era. Eligible for this retrospective study were HIV-positive patients with lymphoma who received autoHCT between 2007 and 2013. A total of 118 patients were included with a median age of 45 years (range 24–66). Underlying diagnoses were diffuse large B cell lymphoma in 47%, Hodgkin lymphoma in 24%, Burkitt lymphoma in 18%, and plasmablastic lymphoma in 7% of patients. Disease status at autoHCT was complete remission in 44%, partial remission (PR) in 38%, and less than PR in 18% of the patients. With a median follow-up of 4 years, 3-year non-relapse mortality, incidence of relapse, progression-free survival (PFS) and overall survival (OS) were 10%, 27%, 63% and 66%, respectively. By multivariate analysis, disease status less than PR but not CD4+ cell count at the time of autoHCT was a significant predictor of unfavorable PFS and OS. In conclusion, in the era of cART and chemoimmunotherapy, the outcome of autoHCT for HIV-related lymphoma is driven by lymphoma-dependent risk factors rather than by characteristics of the HIV infection.
UR - http://www.scopus.com/inward/record.url?scp=85062083130&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062083130&partnerID=8YFLogxK
U2 - 10.1038/s41409-019-0480-x
DO - 10.1038/s41409-019-0480-x
M3 - Article
C2 - 30804486
AN - SCOPUS:85062083130
VL - 54
SP - 1625
EP - 1631
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 10
ER -